Cargando…

Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients

We investigated the spike IgG levels of HIV+ patients on antiretroviral therapy six months after they received their second dose (T2) and six months after the third dose (T3) of the BNT162b2 mRNA vaccine, as well as the influence of different levels of plasma HIV viremia of overall CD4+ cell count a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Basso, Monica, Pirola, Nicole, Pascoli, Susanna, Bragato, Beatrice, Vinci, Antonio, Iannetta, Marco, Colombo, Francesco, Geremia, Nicholas, Martignago, Luca, Rossi, Maria Cristina, Cipriani, Ludovica, Giobbia, Mario, Scotton, Pier Giorgio, Parisi, Saverio Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862719/ https://www.ncbi.nlm.nih.gov/pubmed/36679927 http://dx.doi.org/10.3390/vaccines11010082

Ejemplares similares

SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy
por: Vicenti, Ilaria, et al.
Publicado: (2023)

Sustained virological response after treatment with direct‐acting antivirals can help immune reconstitution in HIV‐HCV coinfected patients even in case of persistent HIV low‐level viremia
por: Basso, Monica, et al.
Publicado: (2020)

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Residual Viremia in Treated HIV(+) Individuals
por: Conway, Jessica M., et al.
Publicado: (2016)

HIV-1 persistent viremia is frequently followed by episodes of low-level viremia
por: Widera, Marek, et al.
Publicado: (2017)

Low CD4 nadir linked to widespread cortical thinning in adults living with HIV
por: Hassanzadeh-Behbahani, Shiva, et al.
Publicado: (2019)

4400 Low CD4 nadir linked to widespread cortical thinning in adults with HIV
por: Hassanzadeh-Behbahani, Shiva, et al.
Publicado: (2020)

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer
por: Di Noia, V., et al.
Publicado: (2022)

Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys
por: Nkambule, Rejoice, et al.
Publicado: (2021)

Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
por: Tsumura, Hideyasu, et al.
Publicado: (2016)

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
por: Mangia, Alessandra, et al.
Publicado: (2022)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy
por: Behrens, Nicole E., et al.
Publicado: (2020)

Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV
por: Touizer, Emma, et al.
Publicado: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Lukaszuk, Krzysztof, et al.
Publicado: (2021)

Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
por: Goupil, Rémi, et al.
Publicado: (2021)

Sensitivity of ventrolateral posterior thalamic nucleus to back pain in alcoholism and CD4 nadir in HIV
por: Zahr, Natalie M., et al.
Publicado: (2019)

1970. SARS-CoV-2 T-cell specific responses in allogeneic hematopoietic stem cell transplant recipients after second and third dose of BNT162b2 mRNA vaccine
por: Marco, Iannetta, et al.
Publicado: (2022)

Robust immune responses after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

Clonal Hematopoiesis Is Associated With Low CD4 Nadir and Increased Residual HIV Transcriptional Activity in Virally Suppressed Individuals With HIV
por: van der Heijden, Wouter A, et al.
Publicado: (2021)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

B Cell Responses to HIV Antigen Are a Potent Correlate of Viremia in HIV-1 Infection and Improve with PD-1 Blockade
por: Nicholas, Katherine J., et al.
Publicado: (2013)

Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017
por: Kassaye, Seble G., et al.
Publicado: (2019)

Comparison of nadir serum concentrations in the extended dosing therapy of natalizumab between American and Japanese multiple sclerosis patients
por: Tanaka, Masami, et al.
Publicado: (2016)

Transient Erythema Elevatum Diutinum Associated With HIV Viremia
por: Rashdan, Hannah, et al.
Publicado: (2023)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study
por: Basso, Monica, et al.
Publicado: (2023)

Residual Viremia Is Preceding Viral Blips and Persistent Low-Level Viremia in Treated HIV-1 Patients
por: Hofstra, Laura Marije, et al.
Publicado: (2014)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose
por: Markewitz, Robert, et al.
Publicado: (2022)

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis
por: Ducloux, Didier, et al.
Publicado: (2021)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
por: Bar-Haim, Erez, et al.
Publicado: (2022)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals
por: Samanovic, Marie I., et al.
Publicado: (2021)

21. Current and Nadir CD4+ Counts Are Associated with Heplisav-B Seroprotection Rates in People with HIV
por: Schnittman, Samuel, et al.
Publicado: (2020)

Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints
por: Sheth, Niki, et al.
Publicado: (2018)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
por: Goonetilleke, Nilu, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lf9n0hnhd4blr4lg717gg5h7av